BioSpace News Archive

Virios Therapeutics, Inc. today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

Autobahn Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of ABX-002 in healthy volunteers.

The health and wellness industry is currently suffering from an excess of pain relief options.

C2N Diagnostics, LLC (“C2N”), a leader in advanced brain health diagnostics, today announced at the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 EU/US Task Force on Blood Biomarkers its next generation test to aid in the diagnosis of Alzheimer’s disease (AD): the PrecivityAD2™ blood test.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies.

PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced they received an $800,000+ direct to Phase II grant from the National Institutes of Health (NIH), to evaluate the immunogenicity of intradermal administration of human papillomavirus virus (HPV) vaccine using their Tropis intradermal (ID) Needle-free Injection System (NFIS).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the first quarter of 2023.

The Optica Foundation issued details on the healthcare work being funded by its 20th Anniversary Challenge.